Translator Disclaimer
11 June 2021 PHARMACOKINETIC, PHARMACODYNAMIC, AND TOXICOLOGY STUDY OF ROBENACOXIB IN RAINBOW TROUT (ONCORHYNCHUS MYKISS)
Juliette Raulic, Francis Beaudry, Guy Beauchamp, Marion Jalenques, Noémie Summa, Stéphane Lair, Wahiba Ait Youcef, Claire Vergneau-Grosset
Author Affiliations +
Abstract

Postoperative antinociception control in fish is currently suboptimal, as commonly used antiinflammatory drugs last for only a few hours at tested temperatures. Therefore, long-acting anti-inflammatory drugs, such as robenacoxib, could improve the welfare of fish. The pharmacokinetics, duration of antinociceptive action, and potential adverse effects of robenacoxib were evaluated through two prospective randomized blinded trials in rainbow trout (Oncorhynchus mykiss). Six healthy rainbow trout received a single IM administration of robenacoxib (2 mg/kg), and two control fish received the same volume of saline IM. Blood samples were collected at predetermined time points for 5 d. Plasma robenacoxib concentrations were measured using high-performance liquid chromatography–high-resolution hybrid orbitrap mass spectrometry and noncompartmental pharmacokinetic analysis. Ten additional rainbow trout received an intralabial injection of 0.05 ml of 2% acetic acid following a previously validated nociceptive model. The treated group (n = 6) received 2 mg/kg of robenacoxib IM and the control group (n = 4) received an equivalent volume of saline IM. The behavior, appetite, and opercular rate of the fish were evaluated every hour for 5 h, then once daily for 3 d. All 12 treated trout and 6 controls underwent histopathologic evaluation. Average maximum plasma concentration (Cmax) was 329.9 ± 137.3 ng/ml observed at 2.1 ± 0.7 h (Tmax) and terminal half-life was 12.6 ± 2.27 h. Plasma concentrations described as antinociceptive in domestic carnivores were measured for 3–4 d. This dose was associated with a significant decrease in rocking behavior (P = 0.017). No adverse effects were detected clinically nor on histopathology. Robenacoxib administered IM at 2 mg/kg appears to be safe and may provide an antinociceptive effect in rainbow trout. This study presents a new therapeutic option to provide long-lasting antinociception in rainbow trout.

Copyright 2021 by American Association of Zoo Veterinarians
Juliette Raulic, Francis Beaudry, Guy Beauchamp, Marion Jalenques, Noémie Summa, Stéphane Lair, Wahiba Ait Youcef, and Claire Vergneau-Grosset "PHARMACOKINETIC, PHARMACODYNAMIC, AND TOXICOLOGY STUDY OF ROBENACOXIB IN RAINBOW TROUT (ONCORHYNCHUS MYKISS)," Journal of Zoo and Wildlife Medicine 52(2), 529-537, (11 June 2021). https://doi.org/10.1638/2020-0130
Accepted: 27 December 2020; Published: 11 June 2021
JOURNAL ARTICLE
9 PAGES


Share
SHARE
RIGHTS & PERMISSIONS
Get copyright permission
Back to Top